Elliot wave - Elopak This is my analysis of Elopak in Norway. We are facing a final push before we might see a potential correction
Update MPCCMPCC went very deep and not as I expected but it didn´t make a new ow on the daily chart.
Please check my previous analysis on MPCC.
Now, I´m looking at this short time analysis and hope to see price turning up from the any of the red Fibonacci levels. Price must not cross the red line for the sho
Institutional Rotation & Setup for Potential Re-Rating in 2025 I have outlined some areas of interest in the chart and some possible ways to reach 2.50 area. Below my personal thoughts behind this.
Institutional Activity & Accumulation
• Mirabella Financial Services LLP holds 10.48% (77.6M shares); estimated VWAP entry: ~1.4217 NOK.
• Alden AS holds 32M shar
NEL ASA close to the BIG supportzone (700days)NEL ASA could reach within the next days/weeks the supportzone from 2015-2017.
The first touch in this zone has the highest probability to show us a bullish reaction.
DNo 09.1.25DNO looks very strong here.
There’s a gap between 11.82 and 11.92 that seems likely to be filled. We’ll probably see a retest around 11.40–11.00 before the price manages to break above 12 NOK again.
Frontline in the end of correction waveFrontline has made its final correction wave, and an upward momentum may follow from here.
The RSI oversold position indicates a bottom. It quickly rose from around 151 to the 160s. It could provide a good return for the first quarter of 2025.
Purchases can be made at these prices with a stop at 151
HAUTO: TP NOK 141,- Generous dividends (+25%) [Pink: HOEGF]Some say Car-carrier (PCTC ) trade macro is challenging in, others claim this comes to pass late '26 or '27. All the while generous dividends are an insurance. Short term movements may meet resistance, must hold +100-ish, looking to medio jan 2025 for more upside.
Conensus TP : NOK 141
New Years Rocket: NYKODE. 20% upside short-term. Nykode Therapeutics ASA, a clinical-stage biopharmaceutical company based in Oslo, Norway, specializes in developing novel immunotherapies, including vaccines for cancer and infectious diseases. Its leading product candidates are VB10.NEO, a cancer neoantigen vaccine in Phase I/IIa trials for variou
Alightment of technical and fundamentalsThe stock is techically stong, with break out characteristic. The company has a good recurring revenue model and with consciousness of health growing, I expect to have it reflected in its revenue as well.
See all popular ideas
Community trends
Stock collections
All stocksTop gainersBiggest losersLarge-capSmall-capLargest employersHigh-dividendHighest net incomeHighest cashHighest profit per employeeHighest revenue per employeeMost activeUnusual volumeMost volatileHigh betaBest performingHighest revenueMost expensivePenny stocksOverboughtOversoldAll-time highAll-time low52-week high52-week lowSee all
Sector 10 matches | Today | 1 week | 1 month | 6 months | Year to date | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|---|
| Energy Minerals | ||||||||
| Finance | ||||||||
| Producer Manufacturing | ||||||||
| Transportation | ||||||||
| Consumer Non-Durables | ||||||||
| Technology Services | ||||||||
| Process Industries | ||||||||
| Communications | ||||||||
| Industrial Services | ||||||||
| Non-Energy Minerals |